Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys

Journal of Bone and Mineral Research

Volumn 13, Issue 11, 1998, Pages 1775-1782

  Binkley, Neil ^a,d   Kimmel, Donald ^b   Bruner, Julia ^a   Haffa, Arlene ^a   Davidowitz, Bradley ^a   Meng, Cliff ^c   Schaffer, Victoria ^c   Green, Jonathan ^c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b CREIGHTON UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d 2245 MSC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DENSITOMETRY; DRUG EFFECT; FEMALE; MENOPAUSE; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OVARIECTOMY; RHESUS MONKEY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; DENSITOMETRY, X-RAY; DIPHOSPHONATES; FEMALE; IMIDAZOLES; MACACA MULATTA; OVARIECTOMY; REGRESSION ANALYSIS;

EID: 0031754524     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.11.1775     Document Type: Article

References (46)

1. Jerome CP, Carlson CS, Register TC, Bain FT, Jayo MJ, Weaver DS, Adams MR 1994 Bone functional changes in intact, ovariectomized, and ovariectomized, hormone-supplemented adult cynomolgus monkeys (Macaca fascicularis) evaluated by serum markers and dynamic histomorphometry. J Bone Miner Res 9:527-540.
2. Pope NS, Gould KG, Anderson DC, Mann DR 1989 Effects of age and sex on bone density in the rhesus monkey. Bone 10:109-112.
3. Johansson EDB, Neill JD, Knobil E 1968 Periovulatory progesterone concentration in the peripheral plasma of the rhesus monkey with a methodologic note on the detection of ovulation. Endocrinology 82:143-148.
4. Neill JD, Johansson EDB, Knobil E 1969 Patterns of circulating progesterone concentrations during the fertile menstrual cycle and the remainder of gestation in the rhesus monkey. Endocrinology 84:45-48.
5. Walker ML 1995 Menopause in female rhesus monkeys. Am J Primatol 35:59-71.
6. Champ JE, Binkley N, Havighurst T, Colman RJ, Kemnitz JW, Roecker EB 1996 The effect of advancing age on bone mineral content of female rhesus monkeys. Bone 19:485-492.
7. Jayo MJ, Jerome CP, Lees CJ, Rankin SE, Weaver DS 1994 Bone mass in female cynomolgus macaques: A cross-sectional and longitudinal study by age. Calcif Tissue Int 54:231-236.
8. Thompson DD, Seedor JG, Quartuccio H, Soloman H, Fioranvanti C, Davidson J, Klein H, Jackson R, Clair J, Frankenfield D, Brown E, Simmons HA, Rodan GA 1992 The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res 7:951-960.
9. Jerome CP, Lees CJ, Weaver DS 1995 Development of osteopenia in ovariectomized cynomolgus monkeys. Bone 17: 403S-408S.
10. Jerome CP, Turner CH, Lees CJ 1997 Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis). Calcif Tissue Int 60:265-270.
11. Kasra M, Grynpas MD 1994 Effect of long-term ovariectomy on bone mechanical properties in young female cynomolgus monkeys. Bone 15:557-561.
12. Mann DR, Gould KG, Collins DC 1990 A potential primate model for bone loss resulting from medical oophorectomy or menopause. J Clin Endocrinol Metab 71:105-110.
13. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577-2586.
14. Lin JH 1996 Bisphosphonates: A review of their pharmacokinetic properties. Bone 18:75-85.
15. Fleisch HA 1997 Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 29:55-62.
16. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443.
17. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541.
18. Green JR, Muller K, Jaeggi K 1994 Preclinical pharmacology of CGP 42,446, a new, potent heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751.
19. Food and Drug Administration 1994 Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Food and Drug Administration, Rockville, MD, U.S.A.
20. Muller K, Wiesenberg I, Jaeggi KA, Green JR 1998 Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat. Drug Res 48:81-86.
21. Arden-Cordone M, Siris ES, Lyles KW, Knieriem A, Newton RA, Schaffer V, Zelenakas K 1997 Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int 60:415-418.
22. Scheffe H 1959 The Analysis of Variance. Wiley, New York, NY, U.S.A.
23. Barlow RE, Bartholomew DJ, Bremner JM, Brunk HD 1972 Statistical Inference Under Order Restrictions. John Wiley & Sons Inc., New York, U.S.A.
24. Snedecor GW, Cochran WG 1980 Statistical Methods, 7th Ed. Iowa State University Press, Ames, IA, U.S.A.
25. Anderson VL, McLean RA 1974 Design of Experiments: A Realistic Approach. Marcel Dekker, Inc., New York, NY, U.S.A., pp. 16-22.
26. Brown MB, Forsythe AB 1974 The small sample behavior of some statistics which test the equality of several means. Technometrics 16:129-132.
27. Meng C, Davis S, Roth A 1993 Robust contrast based trend tests. Proceedings of the 1993 ASA Joint Statistical Meetings - Biopharmaceutical Section 132-137. American Statistical Association, Alexandria, VA, U.S.A.
28. Lindsay R, Hart DM, Sweeney A, Coutts JRT, Clark A 1977 Osteopenia and osteoporosis: Endogenous estrogen and bone loss following oophorectomy. Calcif Tissue Res 22:213-216.
29. Heaney RP, Recker RR, Saville PD 1978 Menopausal changes in calcium balance performance. J Lab Clin Med 92:953-963.
30. Mann DR, Rudman CG, Akinbami MA, Gould KG 1992 Preservation of bone mass in hypogonadal female monkeys with recombinant human growth hormone administration. J Clin Endocrinol Metab 74:1263-1269.
31. Keller ET, Binkley NC, Stebler BS, Kimmel DB, Hall DM, Johnston GM, Michael AG, Ershler WB 1997 Interleukin-6 and lumbar spinal bone loss in the ovariectomized rhesus macaque. J Bone Miner Res 12 (Suppl 1):S338 (abstract).
32. Longscope CL, Hoberg S, Steuterman S, Baran D 1989 The effect of ovariectomy on spine bone mineral density in rhesus monkeys. Bone 10:341-344.
33. Jerome CP, Kimmel DB, McAlister JA, Weaver DS 1986 Effects of ovariectomy on iliac trabecular bone in baboons. Calcif Tissue Int 39:206-208.
34. Miller LC, Weaver DS, McAlister JA, Koritnik DR 1986 Effects of ovariectomy on vertebral trabecular bone in the cynomolgus monkey (Macaca fascicularis). Calcif Tissue Int 38: 62-65.
35. Mazess B, Vetter J, Weaver DS 1987 Bone changes in oophorectomized monkeys: CT findings. J Comput Assist Tomogr 11:302-305.
36. Reginster JY 1995 The role of bisphosphonates in the prevention and treatment of osteoporosis. Clin Rheumatol 14 (Suppl 3):22-25.
37. Green JR, Hornby SB, Evans GP, Muller K 1996 Effect of 1-year treatment with zoledronate (CGP 42,446) on bone mineral density, bone mechanical properties and biochemical markers in the ovariectomized rat. J Bone Miner Res 11 (Suppl 1):S339 (abstract).
38. Bare S, Kimmel D, Binkley N, Schaffer V, Green J 1997 Zoledronate suppresses turnover without affecting mineralization in cancellous bone of the ovariectomized non-human primate. J Bone Miner Res 12 (Suppl 1):S473 (abstract).
39. O'Rourke C, Bare S, Kimmel D, Binkley N, Schaffer V, Green J 1997 Zoledronate suppresses turnover in cortical bone of the ovariectomized non-human primate. J Bone Miner Res 12 (Suppl 1):S473 (abstract).
40. Greenspan SL, Holland Maitland-Ramsey SL, Poku M, Freeman A, Yuan W, Kher U, Gertz B 1996 Alendronate stimulation of nocturnal parathyroid hormone secretion: A mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc Assoc Am Physicians 108:230-238.
41. Lafage HM, Balena R, Battle MA, Shea M, Seedor JG, Klein H, Hayes WC, Rodan GA 1995 Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. J Clin Invest 95:2127-2133.
42. Balena R, Markatos A, Seedor JG, Gentile M, Stark C, Peter CP, Rodan GA 1996 Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J Pharmacol Exp Ther 276: 277-283.
43. Frost HM 1996 Perspectives: A proposed general model of the "mechanostat." Anat Rec 244:139-147.
44. Rodan GA 1997 Bone mass homeostasis and bisphospnonate action. Bone 20:1-4.
45. Polec RB, Yeh SDJ, Shils ME 1971 Protective effect of ascorbic acid, isoascorbic acid and mannitol against tetracycline-induced nephrotoxicity. J Pharmacol Exp Ther 178:152-158.
46. Lew HT, French SW 1966 Tetracycline nephrotoxicity and nonoliguric acute renal failure. Arch Intern Med 118:123-128.